INFU trades 9.6% below Wall Street's consensus target of $15.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes INFU achieves its forward estimates and maintains a stable P/E multiple of 29.8x. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, InfuSystem Holdings, Inc. (INFU) has a Wall Street consensus price target of $15.00, based on estimates from 4 covering analysts. With the stock currently trading at $13.69, this represents a potential upside of +9.6%. The company has a market capitalization of $276M.
Analyst price targets range from a low of $15.00 to a high of $15.00, representing a 0% spread in expectations. The median target of $15.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, INFU trades at a trailing P/E of 30.6x and forward P/E of 29.8x. Analysts expect EPS to grow +12.7% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $19.07, with bear and bull scenarios of $12.01 and $25.13 respectively. Model confidence stands at 48/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 BRTBRT Apartments Corp. | $236M | $12.56 | $21.00 | +67.2% | Buy | — | 5 |
 HCSGHealthcare Services Group, Inc. | $1.7B | $24.28 | $27.33 | +12.6% | Hold | 18.2x | 15 |
 OPRXOptimizeRx Corp. | $164M | $8.76 | $10.25 | +17.0% | Buy | 10.0x | 15 |
 OMCLOmnicell, Inc. | $1.7B | $37.34 | $57.50 | +54.0% | Buy | 15.0x | 20 |
 MDXGMiMedx Group, Inc. | $482M | $3.31 | $7.50 | +126.6% | Buy | — | 15 |
 NVCRNovocure Ltd | $1.5B | $13.28 | $26.00 | +95.8% | Buy | — | 15 |
 MLABMesa Laboratories, Inc. | $718M | $128.25 | $110.00 | -14.2% | Hold | 14.1x | 8 |
 BAXBaxter International Inc. | $13.3B | $25.79 | $23.83 | -7.6% | Hold | 12.3x | 36 |
 BDXBecton, Dickinson and Company | $58.4B | $211.88 | $200.57 | -5.3% | Buy | 16.7x | 34 |
 ICUSeaStar Medical Holding Corporation | $8M | $1.88 | $8.00 | +325.5% | Buy | — | 1 |
Quick answers to the most common questions about buying INFU stock.
The consensus price target for INFU is $15, close to the current price of $13.69 (9.6% implied move). Based on 4 analyst estimates, the stock appears fairly valued near current levels.
INFU has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $15 implies 9.6% upside from current levels.
INFU trades at a forward P/E of 29.7609x, representing a moderate valuation. With analysts targeting $15 (9.6% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $15 for INFU, while the most conservative target is $15. The consensus of $15 represents the median expectation. Our quantitative valuation model projects a bull case target of $25 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
INFU is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month INFU stock forecast based on 4 Wall Street analysts shows a consensus price target of $15, with estimates ranging from $15 (bear case) to $15 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $19, with bear/bull scenarios of $12/$25.
Our quantitative valuation model calculates INFU's fair value at $19 (base case), with a bear case of $12 and bull case of $25. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 48/100.
INFU trades at a forward P/E ratio of 29.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 30.6x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
INFU appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $15 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
INFU analyst price targets range from $15 to $15, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $15 consensus represents the middle ground. Our model's $12-$25 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.